Dong-A ST Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 02:09 am EST
Share
Dong-A ST Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 2,874.15 million compared to KRW 2,845.98 million a year ago. Net income was KRW 21,488.8 million compared to KRW 11,543.59 million a year ago. Basic earnings per share from continuing operations was KRW 2,496.0784 compared to KRW 1,341.1765 a year ago. Diluted earnings per share from continuing operations was KRW 2,496.0784 compared to KRW 1,252.9412 a year ago. Basic earnings per share was KRW 2,496.0784 compared to KRW 1,341.1765 a year ago.
For the nine months, sales was KRW 8,154.29 million compared to KRW 8,045.1 million a year ago. Net income was KRW 26,245.08 million compared to KRW 18,571.44 million a year ago. Basic earnings per share from continuing operations was KRW 3,049.0196 compared to KRW 2,157.8431 a year ago. Diluted earnings per share from continuing operations was KRW 2,915.6863 compared to KRW 1,994.1176 a year ago. Basic earnings per share was KRW 3,049.0196 compared to KRW 2,157.8431 a year ago. Diluted earnings per share was KRW 2,915.6863 compared to KRW 1,994.1176 a year ago.
Dong-A ST Co Ltd is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The Company is involved of the manufacturing and sale of gastric mucosal protective agents, antihistamines, ischemic modifiers, antithrombotic agents, functional dyspepsia, hyperlipidemia, growth hormone, peptic ulcer treatments, cerebral metabolism improvement and hypertension treatments. It produces and sells diagnostic reagents for hepatitis E, I, A and B. In addition, it is engaged in the production and sale of medical devices including implants for artificial joint and maxillofacial surgery. The Company distributes its products in domestic and overseas markets such as Brazil, Turkey and Cambodia.